The Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low dose computed tomography screening for lung cancer versus usual care in a targeted population at risk.

Research output: Contribution to journalArticlepeer-review

  • External authors:
  • Rhian Gabe
  • Irene Simmonds
  • Martyn Kennedy
  • Suzanne Rogerson
  • Nazia Ahmed
  • David Baldwin
  • Richard Booton
  • Ann Cochrane
  • Mike Darby
  • Kevin Franks
  • Sebastian Hinde
  • Sam M. Janes
  • Una MacLeod
  • Mike Messenger
  • Henrik Møller
  • Rachael L. Murray
  • Richard D. Neal
  • Samantha L. Quaife
  • Mark Sculpher
  • Puvan Tharmanathan
  • David Torgerson
  • Matthew E. J. Callister

Abstract

Introduction: Lung cancer is the world’s leading cause of cancer death. Low dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National Lung Screening Trial (NLST). Here we present the Yorkshire Lung Screening Trial (YLST) which will address key questions of relevance for screening implementation.
Methods and analysis: Using a single-consent Zelen’s design, ever-smokers aged 55 to 80 years registered with a GP in Leeds will be randomised (1:1) to invitation to a telephone-based risk-assessment for a Lung Health Check (LHC) or to usual care. The anticipated number randomised by household is 62,980 individuals. Responders at high risk will be invited for LDCT scanning for lung cancer on a mobile van in the community. There will be 2 rounds of screening at an interval of 2 years. Primary objectives are (i) measure participation rates, (ii) compare the performance of PLCOM2012 (threshold ≥1.51%), LLPv2 (threshold ≥5%) and US Preventive Services Task Force (USPSTF) eligibility criteria for screening population selection, and (iii) assess lung cancer outcomes in the intervention and usual care arms. Secondary evaluations include health economics, quality of life, smoking rates according to intervention arm, screening programme performance with ancillary biomarker, and smoking cessation studies.
Ethics and dissemination: The study has been approved by Greater Manchester West research ethics committee (18-NW-0012) and the Health Research Authority following review by the Confidentiality Advisory Group (CAG). Results will be disseminated through publication in peer-reviewed scientific journals, presentation at conferences and on the YLST website.

Bibliographical metadata

Original languageEnglish
JournalBMJ Open
Publication statusAccepted/In press - 8 Jul 2020